Pluripotent Stem Cells & Neurotransmitter is a Breast Cancer Game changer for pain.

Pluripotent Stem Cells & Neurotransmitter is a Breast Cancer Game changer for pain.

Hybrid Medical Analytics research focuses on identifying the cause of chronic pain an ion pump dysfunction in the nervous system that disrupts neurotransmitter signaling.

Breast Cancer pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, Breast Cancer pain can be managed effectively through relatively simple means in up to 90% of Breast Cancer Patients.

Identifying the etiology of pain is important to its management.

Neurotransmitters is showing Promise. billions of neurons in the mammalian brain communicate with each other with liberating chemical messengers that are detected by receptors on adjacent cells.

These chemical messengers, or neurotransmitters, can be ions, amino acids, amino acid derivatives, or large polypeptides.

Gene targeting in embryonic stem cells to generate dopamine-deficient .
Gene targeting in embryonic Pluripotent Stem Cell can be the अन्स्वेर




Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Diagnosed with Breast Cancer Analytics eNotebook CIO Reports a 47% Increase in Ex Vivo Activation

Diagnosed with Breast Cancer Hybrid Medical Analytics eNotebook CIO Reports a 47% Increase in Ex Vivo Activation of Peripheral Stem cell. Hematopoietic or blood stem cell transplants are also
called bone marrow transplants.

Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or
radiation therapy. There are three types of transplants:

• In autologous transplants,is where Breast Cancer patients receive their own stem cells.

• In syngeneic transplants,is where patients receive stem cells from a identical twin.

• In allogeneic transplants, patients receive stem cells from their brother, sister, or parent.

• A person who is not related to the patient (an unrelated donor) also may be used.

Hybrid Medical Analytics is a leader in unrelated donor Stem Cells
The primary use for BMT and PBSCT is to minimize any damage to blood stem cells from Breast Cancer treatment, these stem cells from the bone marrow are removed and preserved before patients receive chemotherapy.
The stem cells are then re-infused into the patient after chemotherapy where they migrate to the bone marrow and begin producing new blood cells.

After the stem cell transplantationentering the bloodstream, the stem cells travel to the bone marrow, where they begin to produce new white blood cells, red blood cells, and platelets in a process known as “engraftment.” Engraftment usually occurs within about 2 to 4 weeks after transplantation.
Doctors monitor it by checking blood counts on a frequent basis. Complete recovery of immune function takes much longer, however—up to several months for autologous transplant recipients
and 1 to 2 years for patients receiving allogeneic or syngeneic transplants. Doctors evaluate the results of various blood tests to confirm that new blood cells are being produced and that
the cancer has not returned. Bone marrow aspiration (the removal of a small sample of bone marrow through a needle for examination under a microscope) can also help doctors determine
how well the new marrow is working.

If you have a relative that can not find a Stem Cell match contact Hybrid Medical Analytics Inc


Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Breast Cancer happens when changes occur in Your DNA

Breast Cancer happens when changes occur in your DNA Your Genes Proteins are not made correctly. A protein may be missing, overproduced, shortened, or assembled with alterations.

We know that Breast Cancer arises when a cell undergoes several molecular changes. These changes can take place over many years, and only when the cell has accumulated a critical number of these changes will become a "cancerous" cells.

At Hybrid Medical Analytics our focus is Genomic Science. Genomic Science studies how each organism has its own unique genome. A human genome has 22 pairs of chromosomes and a pair of sex chromosomes.

The human genome has 25,000 genes spread across all 23 pairs of human chromosomes. When a gene "switches on," it eventually makes a protein and thus Breast Cancer

Genomic converts the gene codes an intermediary molecule called mRNA, this transfer a gene's information from DNA to mRNA which allows us to distinguish mRNA from DNA. Using Hybrid Medical informatics scientist can recommend the proper therapy for treating Breast cancer and extend the life of a Breast Cancer patient



Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems